Sign In
Buy ARVN
$8.03
-0.270 (-3.25%)
At Close: Jul 31, 2026
Arvinas to Report Third Quarter 2025 Financial Results on November 5, 2025
07:00am, Wednesday, 29'th Oct 2025
NEW HAVEN, Conn., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today anno
– In vivo, ARV-806 demonstrated robust and durable KRAS G12D degradation, leading to significant tumor growth inhibition in models of pancreatic, colorectal, and lung cancer –
NEW HAVEN, Conn., Oct. 22, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today anno
Arvinas, Inc. (ARVN) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
11:07am, Wednesday, 22'nd Oct 2025
Arvinas (ARVN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Wall Street Analysts Think Arvinas (ARVN) Could Surge 25.57%: Read This Before Placing a Bet
10:56am, Wednesday, 22'nd Oct 2025
The mean of analysts' price targets for Arvinas (ARVN) points to a 25.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts
– Data demonstrated that vepdegestrant maintained patients' quality of life for statistically significantly longer and delayed worsening of overall health, daily functioning, and symptoms, including
– Presentation to include new patient-reported outcomes (PRO) data from the Phase 3 VERITAC-2 clinical trial – NEW HAVEN, Conn., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN) toda
– ARV-102 was well tolerated in clinical trials for both healthy volunteers and patients with Parkinson's disease –
NEW HAVEN, Conn., Oct. 01, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today anno
Arvinas, Pfizer to grant commercial rights of experimental breast cancer drug to third party
05:50pm, Wednesday, 17'th Sep 2025
Drug developer Arvinas said on Wednesday it will grant commercialization rights of an experimental breast cancer treatment it was developing with Pfizer to a third party.
Arvinas Provides Update on Collaboration with Pfizer and Announces Further Actions to Support Value Creation
04:30pm, Wednesday, 17'th Sep 2025
Arvinas and Pfizer plan to jointly select third party for the out-licensing and commercialization of vepdegestrant Additional cost optimization measures expected to realize total annual savings of mor
Arvinas, Inc. (ARVN) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 Transcript
10:12am, Tuesday, 09'th Sep 2025
Arvinas, Inc. (NASDAQ:ARVN ) Wells Fargo 20th Annual Healthcare Conference 2025 September 4, 2025 12:45 PM EDT Company Participants John Houston - Chairperson, CEO & President Noah Berkowitz - Chief M
Arvinas to Participate in Upcoming Investor Conferences
07:00am, Friday, 29'th Aug 2025
NEW HAVEN, Conn., Aug. 29, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today anno
– Filing based on pivotal Phase 3 VERITAC-2 clinical trial demonstrating statistically significant and clinically meaningful improvement in median progression-free survival versus fulvestrant –
Arvinas, Inc. (ARVN) Q2 2025 Earnings Call Transcript
01:24pm, Wednesday, 06'th Aug 2025
Arvinas, Inc. (NASDAQ:ARVN ) Q2 2025 Earnings Call August 6, 2025 8:00 AM ET Company Participants Andrew R. Saik - CFO & Treasurer Angela M.
